IDEXX Laboratories Inc (IDXX) shareholders
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,599,078 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 5,976,472 | 7.51% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 3,974,472 | 5.04% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IDXX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,170,178 | 10.37% | $4.30B | −195,375 | 0.06% |
| Vanguard Capital Management LLC | 5,152,213 | 6.54% | $2.71B | −30,294 | 0.06% |
| Vanguard Portfolio Management LLC | 3,896,521 | 4.95% | $2.05B | −14,342 | 0.09% |
| State Street Corp | 3,748,660 | 4.76% | $1.97B | +74,475 | 0.06% |
| Invesco Ltd. | 3,611,416 | 4.58% | $1.90B | +261,739 | 0.15% |
| Geode Capital Management, LLC | 2,562,886 | 3.25% | $1.35B | −98,113 | 0.07% |
| Bamco Inc /Ny/ | 1,976,778 | 2.51% | $1.04B | +343,411 | 1.56% |
| Morgan Stanley | 1,356,103 | 1.72% | $713.91M | +40,149 | 0.04% |
| Bank of New York Mellon Corp | 1,193,343 | 1.51% | $628.22M | −311,189 | 0.10% |
| Arrowstreet Capital, Limited Partnership | 1,067,078 | 1.35% | $561.75M | +228,239 | 0.25% |
| Fundsmith LLP | 1,019,887 | 1.29% | $536.91M | −445,899 | 3.93% |
| Blair William & Co/Il | 918,556 | 1.17% | $483.56M | −27,780 | 1.26% |
| Northern Trust Corp | 918,137 | 1.17% | $483.34M | +6,244 | 0.06% |
| UBS Asset Management Americas Inc | 911,489 | 1.16% | $479.84M | +39,700 | 0.09% |
| FMR LLC | 822,643 | 1.04% | $433.07M | +539,667 | 0.02% |
| American Century Companies Inc | 808,358 | 1.03% | $425.55M | +208,427 | 0.19% |
| Capital Research Global Investors | 789,111 | 1.00% | $415.47M | +7,766 | 0.06% |
| JPMorgan Chase & Co | 755,791 | 0.96% | $405.05M | −24,091 | 0.02% |
| Principal Financial Group Inc | 743,246 | 0.94% | $391.30M | −137,943 | 0.19% |
| Goldman Sachs Group Inc | 738,708 | 0.94% | $388.89M | +21,787 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,300 | 74M | 94.5% | 115 / 477 | 505 / 106 | 6M | 5M |
| Q1 2026 | 1,318 | 73M | 93.2% | 125 / 432 | 521 / 174 | 15M | 14M |
| Q4 2025 | 1,386 | 83M | 100.0% | 191 / 484 | 481 / 80 | 16M | 6M |
| Q3 2025 | 1,303 | 73M | 92.9% | 162 / 420 | 488 / 75 | 5M | 6M |
| Q2 2025 | 1,235 | 75M | 95.2% | 199 / 423 | 421 / 94 | 7M | 6M |
| Q1 2025 | 1,143 | 74M | 94.2% | 123 / 466 | 356 / 89 | 8M | 6M |
| Q4 2024 | 1,124 | 72M | 91.8% | 165 / 338 | 440 / 141 | 8M | 10M |
| Q3 2024 | 1,117 | 74M | 93.9% | 105 / 364 | 430 / 87 | 13M | 5M |
| Q2 2024 | 1,110 | 76M | 96.0% | 84 / 421 | 386 / 107 | 6M | 6M |
| Q1 2024 | 1,147 | 76M | 96.3% | 97 / 404 | 413 / 88 | 5M | 4M |
| Q4 2023 | 1,154 | 75M | 95.4% | 189 / 348 | 428 / 81 | 6M | 5M |
| Q3 2023 | 1,060 | 74M | 94.0% | 89 / 386 | 386 / 86 | 4M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
937 funds held IDXX in Q2 2026, 49% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IDXX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,504,327 | 3.18% | $1.32B | 0.06% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,043,087 | 2.59% | $1.08B | 0.06% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 1,709,209 | 2.17% | $899.80M | 0.40% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 1,674,463 | 2.13% | $881.50M | 0.18% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,085,259 | 1.38% | $571.32M | 0.06% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,021,854 | 1.30% | $575.85M | 0.07% | May 31, 2026 |
| Vanguard Growth Index Fund | 942,289 | 1.20% | $496.06M | 0.13% | Jun 30, 2026 |
| Baron Partners Fund | 846,300 | 1.07% | $445.53M | 2.47% | Jun 30, 2026 |
| AMCAP Fund | 732,861 | 0.93% | $412.99M | 0.42% | May 31, 2026 |
| Vanguard Mid-Cap Growth Index Fund | 604,333 | 0.77% | $318.15M | 0.91% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 557,240 | 0.71% | $293.35M | 0.72% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 428,270 | 0.54% | $225.46M | 0.06% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 425,415 | 0.54% | $239.73M | 0.50% | May 31, 2026 |
| iShares Russell Mid-Cap Growth ETF | 391,932 | 0.50% | $206.33M | 0.96% | Jun 30, 2026 |
| Invesco NASDAQ 100 ETF | 338,523 | 0.43% | $190.77M | 0.20% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan Jay Mazelsky | Executive Chair of the Board, Director | 83,803 | 0.11% | Nov 5, 2026 |
| George Fennell | Executive Vice President | 12,182 | 0.02% | Nov 12, 2026 |
| Michael Lane | Executive Vice President | 4,668 | 0.01% | Nov 5, 2026 |
| Sharon E. Underberg | EVP, GC & Corporate Secretary | 7,169 | 0.01% | Nov 5, 2026 |
| Andrew Emerson | EVP, CFO and Treasurer | 4,507 | 0.01% | Aug 24, 2026 |
| Nimrata Hunt | Executive Vice President | 18,301 | 0.02% | Mar 5, 2026 |
| Michael G. Erickson | Executive Vice President | 15,092 | 0.02% | Mar 3, 2026 |
| Michael Perkins Johnson | Executive Vice President | 2,795 | 0.00% | Feb 17, 2026 |
| Martin Alexander Smith | Executive Vice President | 1,603 | 0.00% | Feb 17, 2026 |
| Michael Schreck | Executive Vice President | 2,123 | 0.00% | Feb 17, 2026 |
| Brian P. McKeon | EVP, CFO and Treasurer | 49,600 | 0.06% | Feb 18, 2025 |
| Daniel M. Junius | Director | 2,361 | 0.00% | Nov 5, 2026 |
| Joseph L. Hooley | Director | 373 | 0.00% | Nov 3, 2026 |
| Lawrence D. Kingsley | Director | 9,568 | 0.01% | Sep 9, 2026 |
| Irene Chang Britt | Director | 208 | 0.00% | May 14, 2026 |
| Bruce L. Claflin | Director | 1,721 | 0.00% | May 14, 2026 |
| Sam Samad | Director | 0 | – | May 14, 2026 |
| Stuart Essig | Director | 2,236 | 0.00% | May 14, 2026 |
| Karen Peacock | Director | 102 | 0.00% | May 14, 2026 |
| Sophie V. Vandebroek | Director | 9,078 | 0.01% | May 14, 2026 |
| M. Anne Szostak | Director | 2,320 | 0.00% | May 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| George Fennell Executive Vice President | Nov 10, 2026 | Option exercise | +483 | $206.94 | $99.95K | 12,182 |
| George Fennell Executive Vice President | Nov 10, 2026 | Option exercise | +560 | $178.26 | $99.83K | 11,699 |
| George Fennell Executive Vice President | Nov 10, 2026 | Option exercise | +706 | $141.60 | $99.97K | 11,139 |
| Sharon E. Underberg EVP, GC & Corporate Secretary | Nov 4, 2026 | Sale | −1,055 | $690.02 | $727.97K | 7,169 |
| Sharon E. Underberg EVP, GC & Corporate Secretary | Nov 4, 2026 | Sale | −1,503 | $689.05 | $1.04M | 8,224 |
| Sharon E. Underberg EVP, GC & Corporate Secretary | Nov 4, 2026 | Sale | −6,348 | $688.25 | $4.37M | 9,727 |
| Sharon E. Underberg EVP, GC & Corporate Secretary | Nov 4, 2026 | Option exercise | +8,906 | $288.78 | $2.57M | 16,075 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −331 | $711.95 | $235.65K | 83,803 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −775 | $711.31 | $551.26K | 84,134 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −1,501 | $710.12 | $1.07M | 84,909 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −1,300 | $709.00 | $921.70K | 86,410 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −1,840 | $707.84 | $1.30M | 87,710 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −840 | $707.00 | $593.88K | 89,550 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −240 | $705.59 | $169.34K | 90,390 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −3,950 | $703.45 | $2.78M | 90,630 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −2,136 | $702.21 | $1.50M | 94,580 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −4,540 | $701.36 | $3.18M | 96,716 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −1,667 | $700.33 | $1.17M | 101,256 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −4,075 | $699.33 | $2.85M | 102,923 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Sale | −1,945 | $698.26 | $1.36M | 106,998 |
| Jonathan Jay Mazelsky Executive Chair of the Board, Director | Nov 4, 2026 | Option exercise | +25,140 | $178.26 | $4.48M | 108,943 |
| Michael Lane Executive Vice President | Nov 4, 2026 | Sale | −1,677 | $687.46 | $1.15M | 4,076 |
| Michael Lane Executive Vice President | Nov 4, 2026 | Sale | −2,059 | $689.70 | $1.42M | 5,753 |
| Michael Lane Executive Vice President | Nov 4, 2026 | Sale | −242.944 | $687.85 | $167.11K | 7,812 |
| Daniel M. Junius Director | Nov 4, 2026 | Sale | −500 | $701.68 | $350.84K | 2,361 |
| Daniel M. Junius Director | Nov 4, 2026 | Sale | −700 | $705.78 | $494.05K | 2,861 |
| Joseph L. Hooley Director | Oct 30, 2026 | Award | +48 | $551.21 | $26.46K | 373 |
| Lawrence D. Kingsley Director | Sep 4, 2026 | Sale | −2,203 | $532.08 | $1.17M | 9,568 |
| Lawrence D. Kingsley Director | Sep 4, 2026 | Option exercise | +2,203 | $114.17 | $251.52K | 11,771 |
| Andrew Emerson EVP, CFO and Treasurer | Aug 20, 2026 | Option exercise | +265 | $178.26 | $47.24K | 4,507 |
| Andrew Emerson EVP, CFO and Treasurer | Aug 20, 2026 | Tax withholding | −86 | – | – | 4,421 |
| Joseph L. Hooley Director | Jul 30, 2026 | Award | +49 | $558.80 | $27.38K | 325 |
| George Fennell Executive Vice President | Jun 1, 2026 | Option exercise | +639 | – | – | 10,717 |
| George Fennell Executive Vice President | Jun 1, 2026 | Tax withholding | −284 | $566.79 | $160.97K | 10,433 |
| Lawrence D. Kingsley Director | May 7, 2026 | Option exercise | +82 | – | – | 9,568 |
| Lawrence D. Kingsley Director | May 7, 2026 | Option exercise | +257 | – | – | 9,486 |
| M. Anne Szostak Director | May 7, 2026 | Option exercise | +257 | – | – | 519 |
| Daniel M. Junius Director | May 7, 2026 | Option exercise | +257 | – | – | 3,561 |
| Karen Peacock Director | May 7, 2026 | Option exercise | +101 | – | – | 102 |
| Joseph L. Hooley Director | May 7, 2026 | Option exercise | +158 | – | – | 276 |
| Sophie V. Vandebroek Director | May 7, 2026 | Option exercise | +257 | – | – | 905 |
| Joseph L. Hooley Director | Apr 30, 2026 | Award | +43 | $560.80 | $24.11K | 118 |
| Nimrata Hunt Executive Vice President | Mar 3, 2026 | Sale | −1,758 | $634.57 | $1.12M | 18,141 |
| Sharon E. Underberg EVP, GC & Corporate Secretary | Mar 3, 2026 | Option exercise | +197 | $505.53 | $99.59K | 7,138 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 27, 2026 | Option exercise | +197 | $505.53 | $99.59K | 83,803 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −3,660 | $658.92 | $2.41M | 91,254 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,343 | $656.85 | $882.15K | 97,774 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,488 | $655.85 | $975.90K | 99,117 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,111 | $654.63 | $727.29K | 100,605 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,171 | $653.68 | $765.46K | 101,716 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,669 | $652.49 | $1.09M | 102,887 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −2,859 | $659.75 | $1.89M | 88,395 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,200 | $661.10 | $793.32K | 87,195 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,000 | $662.16 | $662.16K | 86,195 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −2,589 | $663.04 | $1.72M | 83,606 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Option exercise | +23,326 | $141.60 | $3.30M | 106,932 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,281 | $650.67 | $833.51K | 105,651 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −1,095 | $651.49 | $713.38K | 104,556 |
| Jonathan Jay Mazelsky President and CEO, Director | Feb 26, 2026 | Sale | −2,860 | $657.84 | $1.88M | 94,914 |
| Nimrata Hunt Executive Vice President | Feb 26, 2026 | Sale | −2,693 | $661.54 | $1.78M | 19,899 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of IDEXX Laboratories's stock actually held short. Settlement fails (shares not delivered on time) peaked at 824 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel M. Junius Director | Nov 5, 2026 | 1,200 | $839.88K | Nov 4, 2026 | Open Market Purchase |
| Daniel M. Junius Director | Nov 4, 2026 | 500 | $345.84K | Nov 4, 2026 | Open Market Purchase |
| Michael Lane Officer | Nov 4, 2026 | 3,979 | $2.74M | Nov 4, 2026 | Employee Stock Purchase Plan |
| Sharon E. Underberg Officer | Nov 4, 2026 | 8,906 | $6.13M | Nov 4, 2026 | Stock Option Exercise |
| Jonathan Jay Mazelsky Officer, Director | Nov 4, 2026 | 25,140 | $17.68M | Nov 4, 2026 | Stock Option Exercise |
| Lawrence D. Kingsley Director | Sep 4, 2026 | 2,203 | $1.17M | Sep 4, 2026 | Stock Option Exercise |
| M. Anne Szostak Director | May 20, 2026 | 1,344 | $744.01K | May 20, 2026 | Acquired as compensation -- Restricted Stock Units |
| Nimrata Hunt Officer | Mar 3, 2026 | 1,758 | $1.12M | Mar 3, 2026 | Exercised Shares |
| Jonathan Jay Mazelsky Officer, Director | Feb 26, 2026 | 23,326 | $15.34M | Feb 26, 2026 | Stock Option Exercise |
| Nimrata Hunt Officer | Feb 25, 2026 | 2,693 | $1.78M | Feb 25, 2026 | Exercised Shares |
| Sophie V. Vandebroek Director | Feb 17, 2026 | 1,464 | $920.29K | Feb 17, 2026 | Restricted Stock |
| Michael G. Erickson Officer | Feb 17, 2026 | 5,371 | $3.37M | Feb 17, 2026 | Stock Option Exercise |
| George Fennell Officer | Feb 10, 2026 | 11,345 | $7.34M | Feb 10, 2026 | Stock Option Exercise |
| Nimrata Hunt Officer | Nov 7, 2025 | 9,425 | $6.63M | Nov 7, 2025 | Stock Option Exercise |
| M. Anne Szostak Director | Aug 22, 2025 | 2,187 | $1.42M | Aug 22, 2025 | Stock Option Exercise |
Congress trades
34 trades in IDEXX Laboratories reported by 9 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| April McClain Delaney MD06 · child | Sold | Jan 13, 2026 | $1K–15K | Feb 2, 2026 |
| April McClain Delaney MD06 · child | Sold (part) | Oct 16, 2025 | $1K–15K | Nov 4, 2025 |
| Byron Donalds FL19 · spouse | Bought | Sep 4, 2025 | $1K–15K | Oct 7, 2025 |
| Byron Donalds FL19 | Bought | Sep 4, 2025 | $1K–15K | Oct 7, 2025 |
| April McClain Delaney MD06 · child | Sold (part) | Aug 7, 2025 | $1K–15K | Sep 2, 2025 |
| April McClain Delaney MD06 · child | Sold (part) | Jul 9, 2025 | $1K–15K | Aug 5, 2025 |
| Rob Bresnahan PA08 | Bought | May 15, 2025 | $1K–15K | Jun 9, 2025 |
| Jefferson Shreve IN06 | Sold | May 12, 2025 | $100K–250K | Jun 22, 2025 |
| April McClain Delaney MD06 · child | Bought | Apr 9, 2025 | $1K–15K | May 2, 2025 |
| Rob Bresnahan PA08 | Sold | Apr 8, 2025 | $1K–15K | Apr 28, 2025 |
| Jefferson Shreve IN06 | Bought | Apr 7, 2025 | $50K–100K | May 8, 2025 |
| April McClain Delaney MD06 · child | Bought | Apr 7, 2025 | $1K–15K | May 2, 2025 |
| April McClain Delaney MD06 · child | Bought | Apr 4, 2025 | $1K–15K | May 2, 2025 |
| April McClain Delaney MD06 · child | Bought | Apr 1, 2025 | $1K–15K | May 2, 2025 |
| April McClain Delaney MD06 · child | Bought | Mar 14, 2025 | $1K–15K | Apr 2, 2025 |
| Jefferson Shreve IN06 | Bought | Mar 13, 2025 | $15K–50K | Apr 11, 2025 |
| Rob Bresnahan PA08 | Bought | Feb 25, 2025 | $1K–15K | Mar 27, 2025 |
| Diana Harshbarger TN01 · joint account | Bought | Aug 24, 2022 | $1K–15K | Sep 27, 2022 |
| Diana Harshbarger TN01 | Bought | Aug 24, 2022 | $1K–15K | Sep 27, 2022 |
| Peter Meijer MI03 | Sold | Feb 16, 2021 | $1K–15K | Mar 16, 2021 |
| Gilbert Cisneros CA31 | Sold (part) | Oct 9, 2020 | $1K–15K | Nov 5, 2020 |
| Gilbert Cisneros CA31 | Sold (part) | Aug 11, 2020 | $1K–15K | Sep 14, 2020 |
| Gilbert Cisneros CA31 | Sold (part) | Jun 10, 2020 | $1K–15K | Jul 17, 2020 |
| Gilbert Cisneros CA31 | Bought | Apr 9, 2020 | $1K–15K | May 13, 2020 |
| Gilbert Cisneros CA31 | Sold (part) | Jun 3, 2019 | $1K–15K | Jun 18, 2019 |
| Gilbert Cisneros CA31 | Bought | Feb 27, 2019 | $1K–15K | Mar 8, 2019 |
| Gilbert Cisneros CA31 | Bought | Feb 26, 2019 | $1K–15K | Mar 8, 2019 |
| Lamar Smith TX21 | Sold | Jun 2, 2015 | $1K–15K | Jul 13, 2015 |
| K. Michael Conaway TX11 | Sold | Feb 10, 2015 | $1K–15K | Mar 3, 2015 |
| K. Michael Conaway TX11 | Sold | Feb 9, 2015 | $1K–15K | Mar 3, 2015 |
| Lamar Smith TX21 | Bought | Oct 6, 2014 | $1K–15K | Nov 12, 2014 |
| Lamar Smith TX21 | Sold | Apr 2, 2014 | $1K–15K | May 6, 2014 |
| Lamar Smith TX21 | Sold | Mar 11, 2014 | $1K–15K | Apr 7, 2014 |
| Lamar Smith TX21 | Sold | Feb 18, 2014 | $1K–15K | Mar 12, 2014 |
See a number that looks wrong?